Currently, there are 4.89M common shares owned by the public and among those 4.89M shares have been available to trade.
The company’s stock has a 5-day price change of 10.12% and 8.16% over the past three months. NBY shares are trading -90.89% year to date (YTD), with the 12-month market performance down to -94.64% lower. It has a 12-month low price of $0.36 and touched a high of $12.84 over the same period. NBY has an average intraday trading volume of 2.55 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.47%, 11.63%, and -76.19% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Novabay Pharmaceuticals Inc (AMEX: NBY) shares accounts for 0.24% of the company’s 4.89M shares outstanding.
It has a market capitalization of $3.18M and a beta (3y monthly) value of 0.75. The earnings-per-share (ttm) stands at -$47.98. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.93% over the week and 8.38% over the month.
Earnings per share for the fiscal year are expected to increase by 96.90%, and 80.35% over the next financial year.
Looking at the support for the NBY, a number of firms have released research notes about the stock. Ladenburg Thalmann stated their Buy rating for the stock in a research note on September 18, 2019, with the firm’s price target at $1.10. H.C. Wainwright coverage for the Novabay Pharmaceuticals Inc (NBY) stock in a research note released on July 06, 2018 offered a Buy rating with a price target of $4. Laidlaw was of a view on November 15, 2017 that the stock is Buy, while ROTH Capital gave the stock Buy rating on June 05, 2017, issuing a price target of $5.50. Laidlaw on their part issued Buy rating on March 27, 2017.
